TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression

Immunobiology. 2019 Sep;224(5):649-658. doi: 10.1016/j.imbio.2019.07.002. Epub 2019 Aug 9.

Abstract

Transforming growth factor-β (TGF-β) is known to function as a dual role regulatory cytokine for being either a suppresser or promoter during tumor initiation and progression. In solid tumors, TGF-β secreted from tumor microenvironment acts as a suppresser against host immunity, like natural killer (NK) cells, to favor tumor evasion. However, besides solid tumors, the underlying mechanism of how TGF-β regulates leukemogenesis, tumor progression, immunoediting, and NK function is still not clear in detail. In this study, we found that TGF-β induced leukemia MEG-01 and U937 cells to become less sensitive to NK-92MI targeting by down-regulating CD48, a ligand for NK activating receptor 2B4, but not down-regulating other tumor-associated carbohydrate antigens (TACAs). In CD48-knockdown cells, cells responding to NK-92MI targeting displayed a phenotype of less NK susceptibility and cell conjugation. On the other hand, when NK cells were treated with TGF-β, TGF-β suppressed NK recognition, degranulation, and killing activity in time-dependent manner by regulating ICAM-1 binding capacity instead of affecting expressions of activating and inhibitory receptors. Taken together, both leukemia cells and immune NK cells could be regulated by TGF-β through suppressing leukemia cell surface CD48 to escape from host surveillance and down-regulating NK cell surface ICAM-1 binding activity to impair NK functions, respectively. Our results suggested that TGF-β had effect in leukemia similar to that observed in solid tumors but through different regulatory mechanism.

Keywords: CD48; Immunosurveillance; NK cell; TGF-β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD48 Antigen / genetics
  • CD48 Antigen / metabolism*
  • Cell Degranulation
  • Cell Line, Tumor
  • Cytotoxicity, Immunologic / drug effects
  • Disease Susceptibility
  • Humans
  • Immunologic Surveillance
  • Intercellular Adhesion Molecule-1 / immunology
  • Intercellular Adhesion Molecule-1 / metabolism
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism*
  • Leukemia / etiology*
  • Leukemia / metabolism*
  • Leukemia / pathology
  • Lysosomal-Associated Membrane Protein 1 / metabolism
  • Receptors, Natural Killer Cell / metabolism
  • Transforming Growth Factor beta / metabolism*
  • Transforming Growth Factor beta / pharmacology

Substances

  • CD48 Antigen
  • CD48 protein, human
  • Lysosomal-Associated Membrane Protein 1
  • Receptors, Natural Killer Cell
  • Transforming Growth Factor beta
  • Intercellular Adhesion Molecule-1